BindingDB logo
myBDB logout

68 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
6313919 6 C4-substituted 1-beta-D-ribofuranosylpyrazolo[3,4-d]pyrimidines as adenosine agonist analogues.EBI TBA
27485602 183 Similarities and differences in affinity and binding modes of tricyclic pyrimido- and pyrazinoxanthines at human and rat adenosine receptors.EBI Jagiellonian University Medical College
6133953 2 alpha-adrenoreceptor reagents. 1. Synthesis of some 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists and potential antidepressants.EBI TBA
20188574 141 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists.EBI University of Bonn
19569717 251 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity.EBI Institute
12646033 124 Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.EBI Universit£ di Ferrara
9667957 5 Nucleosides and nucleotides. 177. 9-(6,7-dideoxy-beta-D-allo-hept-5- ynofuranosyl)adenine: a selective and potent ligand for P3 purinoceptor-like protein.EBI Hokkaido University
7658429 31 (5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431).EBI Abbott Laboratories
8246243 9 Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine.EBI Kyowa Hakko Kogyo Co., Ltd.
8355252 54 Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.EBI Kyowa Hakko Kogyo Co., Ltd.
1548682 126 8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors.EBI Kyowa Hakko Kogyo Co., Ltd.
1738138 62 Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.EBI NIDDK
1433217 31 Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists.EBI National Institute of Diabetes
1732541 60 Nucleosides and nucleotides. 103. 2-Alkynyladenosines: a novel class of selective adenosine A2 receptor agonists with potent antihypertensive effects.EBI Hokkaido University
1501234 111 Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.EBI Kyowa Hakko Kogyo Co., Ltd.
1495019 57 Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.EBI Hokkaido University
1619615 71 2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.EBI Universit£ di Camerino
1613750 46 Nucleosides and nucleotides. 107. 2-(cycloalkylalkynyl)adenosines: adenosine A2 receptor agonists with potent antihypertensive effects.EBI Yamasa Shoyu Co., Ltd
1895305 75 N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor.EBI University of South Florida
1875349 94 Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.EBI CIBA-GEIGY Corporation
2002461 37 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists.EBI Center for Bio-Pharmaceutical Sciences
2002448 112 N6-substituted adenosine receptor agonists: potential antihypertensive agents.EBI Warner-Lambert Company
1766003 18 Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors.EBI University of South Florida
2374150 193 4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.EBI Pfizer Central Research
2362269 30 2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands.EBI CIBA-GEIGY Corporation
2258897 23 A novel synthesis of xanthines: support for a new binding mode for xanthines with respect to adenosine at adenosine receptors.EBI Merrell Dow Research Institute
2213824 20 Thiazole as a carbonyl bioisostere. A novel class of highly potent and selective 5-HT3 receptor antagonists.EBI Pfizer central Research
2754711 102 Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors.EBI NIDDK
2709373 63 Electrophilic derivatives of purines as irreversible inhibitors of A1 adenosine receptors.EBI NIDDK
2909748 18 N6-bicycloalkyladenosines with unusually high potency and selectivity for the adenosine A1 receptor.EBI Warner-Lambert Company
3385722 42 N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.EBI Warner-Lambert Company
3373486 44 Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives.EBI Universit£ di Camerino
3336027 32 N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.EBI Warner-Lambert Company
2441057 22 Binary drugs: conjugates of purines and a peptide that bind to both adenosine and substance P receptors.EBI TBA
3572985 28 N6-phenyladenosines: pronounced effect of phenyl substituents on affinity for A2 adenosine receptors.EBI TBA
2888894 32 N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.EBI Parke-Davis Pharmaceutical Research Division
3018244 91 N6-substituted N-alkyladenosine-5'-uronamides: bifunctional ligands having recognition groups for A1 and A2 adenosine receptors.EBI TBA
3005574 34 Ribose-modified adenosine analogues as adenosine receptor agonists.EBI TBA
2995663 26 N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists.EBI TBA
6279840 53 Adenosine receptors: targets for future drugs.EBI TBA
9873707 18 Fluorescent probes for adenosine receptors: synthesis and biology of N6-dansylaminoalkyl-substituted NECA derivatives.EBI GlaxoWellcome Medicines Research Center
 22 High selectivity of novel isoguanosine analogues for the adenosine A1 receptorEBI TBA
 13 Discovery of FK453, a novel non-xanthine adenosine A1 receptor antagonistEBI TBA
 44 5-O-Carboxymethyl piperazide derivatives of serotonin: a new class of potent and selective 5-HT1D receptor agonistsEBI TBA
 52 The synthesis and biochemical evaluation of new A1 selective adenosine receptor agonists containing 6-hydrazinopurine moietiesEBI TBA
 8 An explanation of the substituent effect of 1,3,8-trisubstituted xanthines on adenosine A1/A2 affinity.EBI TBA
12014951 139 Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.EBI National Institute of Diabetes & Digestive & Kidney Diseases
10479303 36 Design, synthesis, and evaluation of chromen-2-ones as potent and selective human dopamine D4 antagonists.EBI Warner-Lambert Company
9873377 54 Isoindolinone enantiomers having affinity for the dopamine D4 receptor.EBI Parke-Davis Pharmaceutical Research
9191952 63 Substituted [(4-phenylpiperazinyl)-methyl]benzamides: selective dopamine D4 agonists.EBI Warner-Lambert Company
8496902 139 Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists.EBI National Institute of Diabetes
8230124 92 Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors.EBI Pharmazeutische Chemie
3361572 38 Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists.EBI CIBA-GEIGY Corporation
3361571 30 [1,2,4]Triazolo[4,3-a]quinoxalin-4-amines: a new class of A1 receptor selective adenosine antagonists.EBI Warner-Lambert Company
3172141 35 Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists.EBI Merrell Dow Research Institute
3016270 40 Analogues of 1,3-dipropyl-8-phenylxanthine: enhancement of selectivity at A1-adenosine receptors by aryl substituents.EBI TBA
2795597 43 Linear and proximal benzo-separated alkylated xanthines as adenosine-receptor antagonists.EBI University of South Florida
2724296 113 Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.EBI National Institutes of Health
2213835 66 7-Deaza-2-phenyladenines: structure-activity relationships of potent A1 selective adenosine receptor antagonists.EBI National Institute of Diabetes
2213834 56 Imidazodiazepinediones: a new class of adenosine receptor antagonists.EBI National Institute of Diabetes
2016719 68 1,3,8-trisubstituted xanthines. Effects of substitution pattern upon adenosine receptor A1/A2 affinity.EBI Nova Pharmaceutical Corporation
1992150 60 8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities.EBI Kyowa Hakko Kogyo Co., Ltd.
1895306 13 Synthesis and adenosine receptor affinity of a series of pyrazolo[3,4-d]pyrimidine analogues of 1-methylisoguanosine.EBI Griffith University
1694546 64 Structure-activity relationships of 8-cycloalkyl-1,3-dipropylxanthines as antagonists of adenosine receptors.EBI Vanderbilt University
1613758 95 (E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.EBI Kyowa Hakko Kogyo Co., Ltd
1507211 28 Conformationally restrained, chiral (phenylisopropyl)amino-substituted pyrazolo[3,4-d]pyrimidines and purines with selectivity for adenosine A1 and A2 receptors.EBI Marion Merrell Dow Research Institute